GHK-Cu Gel (Copper(II)-peptide complex)vehicle Gel (placebo comparator)
GHK-Cu Gel (Copper(II)-peptide complex): topical gel, 0.1% w/w; apply a thin film (approx. 0.5 g) once daily for 14 days.
vehicle Gel (placebo comparator): ehicle Gel (placebo comparator
Study summary
This study will evaluate whether a topical gel containing GHK-Cu (a copper(II)-peptide complex) can safely speed up healing of small, standardized skin wounds in healthy adults compared with a matching vehicle gel.
Participants will receive two small punch-biopsy wounds on the upper arm; each wound will be randomly assigned to receive GHK-Cu gel or vehicle gel under identical dressings. Wounds will be photographed and assessed over 3 weeks, with a follow-up visit to evaluate scar quality.
Eligibility
Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Age 18 to 55 years at screening.
* Healthy adult as determined by medical history and limited physical examination.
* Body mass index (BMI) 18.0 to 30.0 kg/m².
* Willing and able to comply with study visits and daily product application for 14 days.
* Willing to avoid applying non-study topical products (including medicated creams, retinoids, acids) to the wound area during the study period.
* For participants of childbearing potential: negative pregnancy test at screening and agreement to use effective contraception through Day 21.
Exclusion Criteria:
* Known allergy or sensitivity to copper, peptides, gel excipients, adhesives, or dressings used in the study.
* History of abnormal wound healing, hypertrophic scarring, or keloid formation.
* Clinically significant dermatologic disease near the intended wound site (e.g., eczema, psoriasis, active infection).
* Diabetes mellitus, peripheral vascular disease, immunodeficiency, or other condition that may impair wound healing (investigator judgment).
* Use of systemic corticosteroids, immunosuppressants, or cytotoxic medications within 30 days prior to Day 0.
* Current smoker or nicotine use (including vaping) within the past 3 months.
* Pregnant or breastfeeding.
* Participation in another interventional clinical study within 30 days prior to screening.
* Any condition that, in the investigator's opinion, would make participation unsafe or could interfere with study assessments.
Primary outcome measure(s)
Time to complete re-epithelialization (days) of each wound, defined as 100% epithelial coverage without drainage, confirmed by blinded clinical assessment and standardized photography. — 21 Days
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.